AFRICAN PHARMACEUTICALS NEED TO PLAY A ROLE IN ADDRESSING AFRICA’S DISEASE BURDEN1/6/2014 12:00:00 AM
“African pharmaceutical entities have got to take the lead in addressing the maladies of the continent. Fundamental research around basic medicines and the way they are administered is required. We also need to find effective ways of getting them to the end-user,” says Kofi Amegashie, Adcock Ingram Managing Executive - Africa.
UNDERSTANDING THE AFRICAN CONSUMER1/6/2014 12:00:00 AM
“To understand any consumer, you have to put yourself in his or her shoes. That’s why you need people who understand, live and breathe the consumer environment in any given market,” says Kofi Amegashie, Adcock Ingram Managing Executive - Africa
Adcock Ingram Delivers Strong Revenue Growth11/27/2013 12:00:00 AM
Margins compress due to weaker rand and sales mix in a challenging South African market Earnings decline due to gearing and tax rate normalisation - FY13 results highlight the need to expand product and geographic presence through international alliances - Highlights that the combination with CFR, which will target high-growth emerging markets, makes strategic sense for Adcock Ingram and South Africa
CFR Pharmaceuticals makes firm offer to acquire Adcock Ingram for R12.6bn11/15/2013 12:00:00 AM
In a joint announcement on the JSE’s SENS today, Adcock Ingram shareholders and the market were informed that the transaction implementation agreement between CFR Pharmaceuticals of Chile and Adcock Ingram has become effective. Showing confidence that it will secure the requisite shareholder support for the transaction, CFR is making a recommended cash and shares offer to acquire Adcock Ingram for R12,6 billion, in what would be one of the most significant inbound investments into South Africa inrecent years.
Webcast of the CFR Pharmaceuticals and Adcock Ingram Announcement 15.11.201311/15/2013 12:00:00 AM
Webcast of the CFR Pharmaceuticals and Adcock Ingram Announcement 15.11.2013
PRESS STATEMENT - Dr. Khotso Mokhele, Chairman of the Board of Adcock11/7/2013 12:00:00 AM
Statement from Dr. Khotso Mokhele, Chairman of the Board of Adcock
Significant shareholder support for CFR’s R12,6bn acquisition of Adcock Ingram10/30/2013 12:00:00 AM
In a cautionary renewal released on the JSE’s SENS today, shareholders and the market were informed that CFR Pharmaceuticals of Chile continues to make good progress with its plans to acquire Adcock Ingram (“Adcock”) for R12,6 billion (US$1,3 billion).
Adcock Ingram Saving the Earth by Using the Earth9/17/2013 12:00:00 AM
Adcock Ingram’s liquid facility in Clayville extends across 50,000m2 of well-developed industrial land and is set up to produce over 12 million litres of oral liquid medication every year. The plant features advanced automated manufacturing and hi-tech, high-speed mechanised lines of the best quality. Perhaps the most laudable aspect of the plant is its innovative use of green technologies which have significantly reduced power consumption, costs, and the company’s carbon footprint.
Adcock Ingram and CFR reach agreement regarding the proposed creation of a uniquely diversified emerging markets pharmaceuticals company9/11/2013 12:00:00 AM
Adcock Ingram and CFR have entered into a transaction implementation agreement regarding a potential cash and shares offer by CFR to acquire 100% of the issued ordinary share capital of Adcock Ingram
New Executive Appointment at Adcock Ingram8/29/2013 12:00:00 AM
Craig St John Ayre has joined Adcock Ingram as the Commercial Executive – Business Intelligence.
Adcock Ingram Fire-Fighters to compete in national finals of competition8/19/2013 12:00:00 AM
Adcock Ingram Healthcare has gained two places in the National Finals of the Mutual Risk Group (MRG) Fire Competition to be held later this year
Adcock Ingram Enters Into Discussions With CFR Pharmaceuticals To Create A Leading Global Emerging Markets Pharmaceuticals Company7/3/2013 12:00:00 AM
The Independent Board of Adcock Ingram today announced that it has entered into discussions with CFR Pharmaceuticals S.A. (CFR) – a multinational emerging markets pharmaceutical company based in Chile – that may lead to CFR making a cash and share offer to acquire 100% of Adcock’s entire share capital. The transaction, if implemented, would create a merged company with combined revenues of approximately US$1.3 billion (approximately ZAR12.1 billion).